应用门冬氨酸钾镁治疗急性心肌梗死的疗效观察

The Clinical Observation of Potassium Magnesium Aspartate in the Treatment of Acute Myocardial Infarction

目的 :探讨门冬氨酸钾镁在急性心肌梗死治疗中的应用价值。方法 :采用随机、单盲将 12 6例急性心肌梗死患者分为门冬氨酸钾镁治疗组和对照组 ,治疗组在急性心肌梗死的当日 ,静滴门冬氨酸钾镁 10 0ml,第 2～ 5日静滴剂量每日 5 0ml ,第 6日改为口服。观察两组 1个月内心律失常、心力衰竭的发生率和病死率。结果 :治疗组与对照组恶性心律失常发生率分别为 11%和 2 6% (P <0 .0 5 ) ;心衰发生率分别为 11%和 2 8% (P <0 .0 5 ) ;1个月内病死率分别为 9%和 2 5 % (P <0 .0 5 )。结论

Objective:To observe the benefits of potassium-magnesium aspartate in acute myocardial infarction .Methods:One hundred and twenty-six patients were prospectively ,randomly assigned in a one-blind fashion to receive intravenous potassium-magnesium aspartate (magnesium group, n=61)or controls (placebo group, n=65). We prospectively examined the effect of potassium-magnesium aspartate treatment on the incidence of arrhythmia and heart failure ,and the mortality in hospital .Results:The morbility of arrhythmia in magnesium and placebo group were 11% and 26% (P<0 05), respectively ;the incidence of heart failure in the two groups were 11% and 26% (P<0.05), respectively, the incidence of heart failure in the two groups were 11% and 28% (P<0.05), respectively, and the the mortality in the two groups were 8.2% and 20% (P<0.05), respectively .Conclusions:Potassium-magnesium aspartate is a safe and useful therapy in reducing the incidence of arrhythmia, heart failure and the mortality after acute myocardial infarction.